Premium
Toxicity Study of Cytosine Arabinoside and Methotrexate in the Maintenance Therapy of Childhood Leukemia. A Southwest Oncology Group Study
Author(s) -
NITSCHKE RUPRECHT,
KOMP DIANE M.,
MORGAN SAMUEL K.,
STARLING KENNETH A.,
VIETTI TERESA J.
Publication year - 1978
Publication title -
the journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.92
H-Index - 116
eISSN - 1552-4604
pISSN - 0091-2700
DOI - 10.1002/j.1552-4604.1978.tb02433.x
Subject(s) - methotrexate , toxicity , medicine , cytosine , cytarabine , vomiting , leukemia , maintenance therapy , chemotherapy , pharmacology , acute lymphocytic leukemia , oncology , gastroenterology , lymphoblastic leukemia , chemistry , dna , biochemistry
In a toxicity study to determine the feasibility of treating patients with acute lymphocytic leukemia (ALL) using an intravenous combination of cytosine arabinoside (Ara-C) and methotrexate (MTX), the drugs were given either simultaneously or sequentially every two weeks. Twenty-nine patients were studied, 17 treated simultaneously, 12 treated sequentially. The tolerated doses of Ara-C and MTX were 60 mg/m2 and 90 mg/m2, respectively, for the simultaneous treatment schedule and 90 mg/m2 and 150 mg/m2, respectively, for the sequential treatment schedule. The dose-limiting factor of the drug combination was gastrointestinal toxicity. The observed recurrent vomiting on both schedules rendered the treatment unsuitable for maintenance therapy.